ByTrending Posts
Could Chai’s $70 Million OpenAI-Backed Funding Propel the Next Leap…
Key Highlights Breakthrough Funding and Industry BackingThe Series A round brings Chai Discovery’s total capital to $100 million,…
Is Illinois’ Ban on AI in Mental Healthcare a Turning Point for…
Key Highlights Background and Impetus for the BanDriven by incidents where AI chatbots posed risks—including cases suggesting harmful…
Can Zimmer Biomet’s $177 Million AI-Driven Acquisition of…
Key Highlights Strategic Acquisition Enhances Zimmer Biomet’s Robotics LeadershipZimmer Biomet’s acquisition of Monogram Technologies, announced in July 2025,…
How Will Eli Lilly’s New $220,000 sq ft Hyderabad Tech Hub and…
Key Highlights Strategic Digital Operations Hub Anchors Eli Lilly’s Global Innovation AmbitionsEli Lilly’s Hyderabad facility located in Gachibowli…
Is AbbVie’s $15.4 Billion Q2 Surge and Strategic…
Key Highlights Strong Q2 Financial Performance and Guidance RaiseAbbVie reported Q2 2025 net revenues of $15.423 billion, up…
How Will METiS Technologies’ RMB 400 Million Series…
Key Highlights Strong Capital Infusion to Accelerate AI-Driven Nanotechnology DevelopmentThe recent RMB 400 million (~$57 million) financing round…
How Will Lantern Pharma’s PredictBBB.ai Advance with 94%…
Key Highlights Breakthrough AI Methodology Sets New Industry BenchmarkLantern’s proprietary ensemble of machine learning algorithms—including logistic regression, random…
Can Phare Bio’s AI-Driven Antibiotic Discovery Win Herald…
Key Highlights Harnessing Generative AI to Revolutionize Antibiotic DiscoveryPhare Bio leverages cutting-edge AI to drastically shorten the traditionally…
Will AbbVie’s $1 Billion Move to Acquire Gilgamesh…
Key Highlights Advanced Acquisition Talks Reflect Growth Strategy Amid Sector InterestAbbVie, following over $20 billion in acquisitions since…
Trending Posts
Latest Stories
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance Accelerate the Next Wave of Antibody and NANOBODY® Innovation in Inflammatory Diseases?
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi,…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles,…
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing…
Gallery
